AGONISTIC LTBR ANTIBODIES AND BISPECIFIC ANTIBODIES COMPRISING THEM

The invention relates to novel antibodies that bind to lymphotoxin beta receptor (LTBR) and to bispecific antigen binding molecules comprising these novel LTBR antibodies and an antigen binding domain that binds a tumor associated antigen, in particular to Fibroblast Activation Protein (FAP), to met...

Full description

Saved in:
Bibliographic Details
Main Authors KUNZ, Leo Frederik, LECLAIR, Stephane, MUNDIGL, Olaf, NIKOLOV, Miroslav, HOSSE, Ralf, BIANCHI, Roberta, GEORGES, Guy, MENDE, Fanny, BRYDON, Michelle Victoria, DUERR, Harald, BORMANN, Felix, DENGL, Stefan, LEISIBACH, Desirée, HANISCH, Lydia Jasmin, HEIDRICH, Monika, UMAÑA, Pablo, WAGNER, Cornelia
Format Patent
LanguageEnglish
Published 13.06.2024
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention relates to novel antibodies that bind to lymphotoxin beta receptor (LTBR) and to bispecific antigen binding molecules comprising these novel LTBR antibodies and an antigen binding domain that binds a tumor associated antigen, in particular to Fibroblast Activation Protein (FAP), to methods of producing these molecules and to methods of using the same.
Bibliography:Application Number: AU20220423749